Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: A case report

Japanese Journal of Clinical Oncology

Volumn 46, Issue 9, 2016, Pages 875-878

  Tanaka, Ryota ^a   Maruyama, Hiroshi ^a   Tomidokoro, Yasushi ^a   Yanagiha, Kumi ^a   Hirabayashi, Takumi ^a   Ishii, Akiko ^a   Okune, Mari ^a   Inoue, Sae ^a   Sekine, Ikuo ^a   Tamaoka, Akira ^a   Fujimoto, Manabu ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Adverse events; Immunoglobulin; Melanoma; Neuropathy; Nivolumab

Indexed keywords

GADOLINIUM; IMMUNOGLOBULIN; NIVOLUMAB; PREDNISOLONE; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ADVANCED CANCER; AGED; ARTICLE; ATAXIA; CANCER STAGING; CASE REPORT; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DAILY LIFE ACTIVITY; DEMYELINATION; DETERIORATION; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSARTHRIA; FEMALE; FINGER TREMOR; GUILLAIN BARRE SYNDROME; HAND PARESTHESIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPESTHESIA; HYPOALGESIA; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; MOTOR CONTROL; MOTOR NERVE BLOCK; MOTOR NERVE CONDUCTION; NERVE BIOPSY; NERVE POTENTIAL; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROREHABILITATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; POLYRADICULONEUROPATHY; SENSORY DYSFUNCTION; SENSORY NERVE; SIDE EFFECT; SURAL NERVE; TASTE DISORDER; TENDON REFLEX; TREATMENT DURATION; VERY ELDERLY; VISUAL ACUITY; WEAKNESS; CERVICAL SPINAL CORD; DIAGNOSTIC IMAGING; GUILLAIN-BARRE SYNDROME; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SKIN NEOPLASMS;

ACTIVITIES OF DAILY LIVING; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CERVICAL CORD; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MELANOMA; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SKIN NEOPLASMS;

EID: 84994173292     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyw090     Document Type: Article

References (19)

1. Postow, M, Callahan, MK, Wolchok, JD. Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J 2011;17:372-8
2. Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35
3. Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13
4. Topalian, SL, Sznol, M, McDermott, DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30
5. Robert, C, Long, GV, Brady, B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30
6. Di Giacomo, AM, Biagioli, M, Maio, M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010;37:499-507
7. Schadendorf, D, Hodi, FS, Robert, C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-94
8. Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-23
9. Bot, I, Blank, CU, Boogerd, W, Brandsma, D. Neurological immunerelated adverse events of ipilimumab. Pract Neurol 2013;13:278-80
10. Liao, B, Shroff, S, Kamiya-Matsuoka, C, Tummala, S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014;16:589-93
11. Wilgenhof, S, Neyns, B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 2011;22:991-3
12. Conry, RM, Sullivan, JC, Nabors, LB. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res 2015;3: 598-601
13. Luke, JJ, Lezcano, C, Hodi, FS, Murphy, GF. Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab. J Clin Oncol 2015;33:e32-5
14. Johnson, DB, Wallender, EK, Cohen, DN, et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res 2013;1:373-7
15. Hughes, RA, Cornblath, DR. Guillain-Barre syndrome. Lancet 2005; 366:1653-66
16. Hughes, RA, Swan, AV, van Doorn, PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2012;7:CD002063
17. Ruts, L, Drenthen, J, Jacobs, BC, van Doorn, PA. Distinguishing acuteonset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010;74:1680-6
18. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a Joint Task Force of the EFNS and the PNS-First Revision. J Peripher Nerv Syst 2010;15:1-9
19. Gorson, KC, Allam, G, Ropper, AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-8